S Larsson1, L S Lohmander2, A Struglics3. 1. Department of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address: staffan.larsson@med.lu.se. 2. Department of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden; Research Unit for Musculoskeletal Function and Physiotherapy, University of Southern Denmark, Denmark; Department of Orthopaedics and Traumatology, University of Southern Denmark, Denmark. Electronic address: stefan.lohmander@med.lu.se. 3. Department of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden. Electronic address: andre.struglics@med.lu.se.
Abstract
OBJECTIVE: To validate a modified ligand-binding assay for the detection of aggrecanase generated aggrecan fragments with the ARGS neoepitope in synovial fluid (SF) and blood, and to verify the identity of aggrecan fragments found in blood. DESIGN: An enzyme-linked immunosorbent assay (ELISA) on the Meso Scale Discovery (MSD) platform for detection of ARGS-aggrecan was validated, using a standard made from recombinant human aggrecan. Matched samples of SF, serum, plasma, and urine were obtained from 36 subjects at different time points after knee injury, and analysed for ARGS-aggrecan content. Aggrecan was purified from serum and plasma pools and analysed by Western blot. RESULTS: The limits of quantification for the ARGS-aggrecan assay was between 0.2 and 0.025 pmol ARGS/ml, and the sensitivity of the assay was improved two-fold compared to when using a standard purified from human donors. The ARGS concentrations were highest in SF (mean, range; 3.02, 0.36-30.22 pmol/ml), 20 times lower in the blood samples (0.14, 0.055-0.28 pmol/ml serum and 0.13, 0.053-0.28 pmol/ml plasma), and 80 times lower in urine (0.036, below detection - 0.087 pmol/ml). Serum-ARGS and plasma-ARGS concentrations were similar, and correlated (r(S) = 0.773, P < 0.001). SF concentration correlated with serum concentrations (r(S) = 0.420, P = 0.011). In blood, we identified 129-138 kDa aggrecan fragments containing the ARGS neoepitope. CONCLUSIONS: This novel ARGS-aggrecan assay is highly sensitive and suited for analysis of SF and blood samples. Both SF and blood contains ARGS-aggrecan, and ARGS concentrations in SF and serum are correlated.
OBJECTIVE: To validate a modified ligand-binding assay for the detection of aggrecanase generated aggrecan fragments with the ARGS neoepitope in synovial fluid (SF) and blood, and to verify the identity of aggrecan fragments found in blood. DESIGN: An enzyme-linked immunosorbent assay (ELISA) on the Meso Scale Discovery (MSD) platform for detection of ARGS-aggrecan was validated, using a standard made from recombinant human aggrecan. Matched samples of SF, serum, plasma, and urine were obtained from 36 subjects at different time points after knee injury, and analysed for ARGS-aggrecan content. Aggrecan was purified from serum and plasma pools and analysed by Western blot. RESULTS: The limits of quantification for the ARGS-aggrecan assay was between 0.2 and 0.025 pmol ARGS/ml, and the sensitivity of the assay was improved two-fold compared to when using a standard purified from human donors. The ARGS concentrations were highest in SF (mean, range; 3.02, 0.36-30.22 pmol/ml), 20 times lower in the blood samples (0.14, 0.055-0.28 pmol/ml serum and 0.13, 0.053-0.28 pmol/ml plasma), and 80 times lower in urine (0.036, below detection - 0.087 pmol/ml). Serum-ARGS and plasma-ARGS concentrations were similar, and correlated (r(S) = 0.773, P < 0.001). SF concentration correlated with serum concentrations (r(S) = 0.420, P = 0.011). In blood, we identified 129-138 kDa aggrecan fragments containing the ARGS neoepitope. CONCLUSIONS: This novel ARGS-aggrecan assay is highly sensitive and suited for analysis of SF and blood samples. Both SF and blood contains ARGS-aggrecan, and ARGS concentrations in SF and serum are correlated.
Authors: Hope C Davis; Jeffery T Spang; Richard F Loeser; Staffan Larsson; Veronica Ulici; J Troy Blackburn; R Alexander Creighton; Ganesh M Kamath; Joanne M Jordan; Stephen W Marshall; Brian Pietrosimone Journal: Knee Date: 2018-03-07 Impact factor: 2.199
Authors: Robert L Trevino; Jonathan Stoia; Michel P Laurent; Carol A Pacione; Susan Chubinskaya; Markus A Wimmer Journal: Biotribology (Oxf) Date: 2016-11-30
Authors: Ellen van der Aar; Henri Deckx; Sonia Dupont; Ann Fieuw; Stephane Delage; Staffan Larsson; André Struglics; L Stefan Lohmander; Agnes Lalande; Emilie Leroux; David Amantini; Paul Passier Journal: Clin Pharmacol Drug Dev Date: 2021-12-02
Authors: S Roberts; H Evans; K Wright; L van Niekerk; B Caterson; J B Richardson; K H S Kumar; J H Kuiper Journal: Osteoarthritis Cartilage Date: 2015-05-21 Impact factor: 6.576
Authors: Yunyun Luo; Yi He; Ditte Reker; Natasja Stæhr Gudmann; Kim Henriksen; Ole Simonsen; Christoph Ladel; Martin Michaelis; Ali Mobasheri; Morten Karsdal; Anne-Christine Bay-Jensen Journal: Int J Mol Sci Date: 2018-11-06 Impact factor: 5.923
Authors: Anne Sofie Siebuhr; Daniela Werkmann; Anne-C Bay-Jensen; Christian S Thudium; Morten Asser Karsdal; Benedikte Serruys; Christoph Ladel; Martin Michaelis; Sven Lindemann Journal: Int J Mol Sci Date: 2020-08-20 Impact factor: 5.923
Authors: Garima Dwivedi; Lisa Flaman; Begum Alaybeyoglu; André Struglics; Eliot H Frank; Susan Chubinskya; Stephen B Trippel; Vicki Rosen; Murat Cirit; Alan J Grodzinsky Journal: Arthritis Res Ther Date: 2022-08-18 Impact factor: 5.606